Braveheart Investments Regulatory News (BRH)

3 March 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Operational Update and Strategic Investments

Braveheart (AIM:BRH), the fund management and strategic investment group, is pleased to announce that it has launched its new look website www.braveheartgroup.co.uk, which now includes comprehensive information about our Strategic Investments. Braveheart is also pleased to provide an operational update on its strategic investments.

Pharm 2 Farm Limited ("P2F") (holding 51.72%)

P2F has launched its new website https://www.pharm2farm.org/, designed primarily to target customers in the plant nutrition markets, which is the focus of current sales. P2F's coated nanoparticles, with improved bioavailability over traditional materials, have been shown in trials to improve the health and growth rate of many crops.

P2F's nanoparticles are also applicable to a wide range of non-plant markets and the company is actively exploring these. For example, there are a number of potential applications for nanoparticles in body imaging and other medical applications.

The company has now opened its new office and laboratory at MediCity in Nottingham, UK.

Kirkstall Limited ("Kirkstall") (holding 64.67%)

Braveheart has provided a further £60,000 investment to Kirkstall in the form of a convertible loan, to provide working capital. Under the terms of the loan, if converted into equity, Braveheart's shareholding would increase from 64.5% to 80%.

Gyrometric Systems Limited ("Gyrometric") (holding 19.95%)

Following a successful exhibition of Gyrometric's products at the Eurasia Boat Show in Istanbul, Gyrometric has signed a Memorandum of Understanding with Turkish company Gani Gemi Ve Is Makinaları Tic. Ltd ("Gani"). The two companies have agreed to work together to bring Gyrometric's products to the marine market in Turkey and neighbouring countries, where Gani is a leading installer of engines and other heavy equipment for both ship and rail industries.

Phasefocus Holdings Limited ("Phasefocus") (holding 21.20%)

We are pleased to announce that Heads of Terms have been agreed for Braveheart to increase its equity investment in Phasefocus. Under the Heads of Terms, Braveheart will invest £86,000 to increase its shareholding in the company from 21.2% to 25%.

Following the investment, Braveheart will take a seat on the company's board.

Paraytec Limited ("Paraytec") (holding 100%)

The second round of end user trials are underway on Paraytec's Innovate UK funded R&D project ("NEXUS"), which is developing instrumentation for measuring protein aggregation in biopharmaceuticals. Trials are ongoing with GlaxoSmithKline and Medimmune and expected to complete in March 2020.

For further information: